Literature DB >> 11751963

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses.

Emanuele Fanales-Belasio1, Sonia Moretti, Filomena Nappi, Giovanni Barillari, Fabiola Micheletti, Aurelio Cafaro, Barbara Ensoli.   

Abstract

Vaccination of cynomolgus monkeys with the biologically active HIV-1 Tat protein induces specific Th1 responses, including CTLs. Similar responses are also induced by vaccination with tat DNA, but not by vaccination with inactivated Tat or Tat peptides. This suggested that the native Tat protein may act differently on APC as compared with inactivated Tat or peptide Ag. In this study, we show that biologically active Tat is very efficiently taken up by monocyte-derived dendritic cells (MDDC) in a time (within minutes)- and dose-dependent (starting from 0.1 ng/ml) fashion, whereas uptake is very poor or absent with other APC, including T cell blasts and B lymphoblastoid cell lines. Although maturation of MDDC reduces their pino/phagocytic activity, mature MDDC take up Tat much more efficiently than immature cells. In addition, Tat uptake is abolished or greatly hampered by oxidation/inactivation of the protein or by performing the experiments at 4 degrees C, suggesting that MDDC take up native Tat by a receptor-mediated endocytosis. After uptake, active Tat protein induces up-regulation of MHC and costimulatory molecules and production of IL-12, TNF-alpha, and beta chemokines, which drive Th1-type immune response. In contrast, these effects are lost by oxidation and inactivation of the protein. Finally, native Tat enhances Ag presentation by MDDC, increasing Ag-specific T cell responses. These data indicate that native Tat selectively targets MDDC, is taken up by these cells via specialized pathways, and promotes their maturation and Ag-presenting functions, driving Th1-type immune responses. Thus, Tat can act as both Ag and adjuvant, capable of driving T cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751963     DOI: 10.4049/jimmunol.168.1.197

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Effect of the redox state on HIV-1 tat protein multimerization and cell internalization and trafficking.

Authors:  Raffaella Pierleoni; Michele Menotta; Antonella Antonelli; Carla Sfara; Giordano Serafini; Sabrina Dominici; Maria Elena Laguardia; Annalisa Salis; Gianluca Damonte; Lucia Banci; Marco Porcu; Paolo Monini; Barbara Ensoli; Mauro Magnani
Journal:  Mol Cell Biochem       Date:  2010-08-20       Impact factor: 3.396

Review 2.  HIV-1 and the hijacking of dendritic cells: a tug of war.

Authors:  Marie Larsson
Journal:  Springer Semin Immunopathol       Date:  2005-01

3.  Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape.

Authors:  Biswanath Majumder; Michelle L Janket; Elizabeth A Schafer; Keri Schaubert; Xiao-Li Huang; June Kan-Mitchell; Charles R Rinaldo; Velpandi Ayyavoo
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

Authors:  Flavia Ferrantelli; Stefano Buttò; Aurelio Cafaro; Britta Wahren; Barbara Ensoli
Journal:  Springer Semin Immunopathol       Date:  2006-09-16

5.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

Review 6.  Dendritic-cell interactions with HIV: infection and viral dissemination.

Authors:  Li Wu; Vineet N KewalRamani
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

7.  Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes.

Authors:  Rebecca Voltan; Arianna Castaldello; Egidio Brocca-Cofano; Giuseppe Altavilla; Antonella Caputo; Michele Laus; Katia Sparnacci; Barbara Ensoli; Silvia Spaccasassi; Marco Ballestri; Luisa Tondelli
Journal:  Pharm Res       Date:  2007-05-03       Impact factor: 4.200

8.  Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis.

Authors:  Laura Fantuzzi; Cristina Purificato; Karim Donato; Filippo Belardelli; Sandra Gessani
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.

Authors:  Barbara Ensoli; Stefania Bellino; Antonella Tripiciano; Olimpia Longo; Vittorio Francavilla; Simone Marcotullio; Aurelio Cafaro; Orietta Picconi; Giovanni Paniccia; Arianna Scoglio; Angela Arancio; Cristina Ariola; Maria J Ruiz Alvarez; Massimo Campagna; Donato Scaramuzzi; Cristina Iori; Roberto Esposito; Cristina Mussini; Florio Ghinelli; Laura Sighinolfi; Guido Palamara; Alessandra Latini; Gioacchino Angarano; Nicoletta Ladisa; Fabrizio Soscia; Vito S Mercurio; Adriano Lazzarin; Giuseppe Tambussi; Raffaele Visintini; Francesco Mazzotta; Massimo Di Pietro; Massimo Galli; Stefano Rusconi; Giampiero Carosi; Carlo Torti; Giovanni Di Perri; Stefano Bonora; Fabrizio Ensoli; Enrico Garaci
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

Review 10.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.